TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04751630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
Study: NCT06590376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: midwifery care based on swanson care theory
Description: All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
Study: NCT06668116

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine 0,1%
Description: The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine 0,1%
Description: The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness.

Intervention type: OTHER
Group type: OTHER
Intervention: NaCl (placebo)
Description: 0.9 % NaCl solution (saline) injection

Intervention type: OTHER
Group type: OTHER
Intervention: NaCl (placebo)
Description: 0.9 % NaCl solution (saline) injection
Study: NCT06669663

Intervention type: DRUG
Intervention: Pimonidazole hydrochloride (Hypoxyprobe™-1)
Description: Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
Study: NCT05962996

Intervention type: DEVICE
Intervention: Pupillometry
Description: Measurement of pain levels by pupillometry during the insertion of a deep venous catheter

Intervention type: DEVICE
Intervention: Pupillometry
Description: Measurement of pain levels by pupillometry during the insertion of a deep venous catheter

Intervention type: DEVICE
Intervention: Pupillometry
Description: Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
Study: NCT06613048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening).
Study: NCT05158309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8% Capsaicin patch
Description: Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
Study: NCT05117229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MetaWear Sensor
Description: Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
Study: NCT06614309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
Study: NCT04644289

Intervention type: DRUG
Group type: OTHER
Intervention: olaparib
Description: Olaparib tablets are administrated orally 300 mg twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: olaparib
Description: Olaparib tablets are administrated orally 300 mg twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: durvalumab
Description: Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
Study: NCT05509231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Description: Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Description: Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable glove and arm sleeve device to measure movement
Description: Sign language and other fine motor skills activities using wearable technology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable glove and arm sleeve device to measure movement
Description: Sign language and other fine motor skills activities using wearable technology.
Study: NCT06614309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
Study: NCT06541119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy programme
Description: * Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs
Study: NCT05175729

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmologic Examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmologic Examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
Study: NCT04827875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal
Study: NCT06285331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Bed
Description: The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual
Description: The clinicians will perform passive leg raising on patients by touching their legs physically.
Study: NCT06462638

Intervention type: OTHER
Intervention: Neurobehavioral states and physiological parameters evaluation
Description: Each individual infant included in the study will be assessed 3 times a week for at least two weeks: specifically, two detections of neurobehavioral states in response to interaction with the mother, two detections with the father, and two detections with the nurse(s) will be made.~For each infant involved in the study, an audio/video recording of cradle movements and vocalizations will be made at 3 different consecutive times (5 minutes each): baseline; recording during interaction with either parent or nurse; post-interaction assessment.~The parent or nurse is asked to interact freely with the baby, choosing whether to use voice and touch or only one of the sensory stimulation channels. During the interactions, parents and nurse will in turn be assessed relative to some basic physiological parameters through the use of a band applied to the chest; the infant's physiological parameters during the 3 times will also be recorded.

Intervention type: OTHER
Intervention: Maternal vocal pitch evaluation to assess depressive/anxious state
Description: Regarding the assessment of any depressive/anxious states of the mother, as an additional support to the self-report questionnaires the maternal vocal pitch will be specifically assessed through the Talking about software (AI algorithm applied to maternal postpartum depression research).
Study: NCT04971421

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA - circulating tumor DNA
Description: lcWGS and WGS of circulating tumor DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA - circulating tumor DNA
Description: lcWGS and WGS of circulating tumor DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA - circulating tumor DNA
Description: lcWGS and WGS of circulating tumor DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP - Tumor Educated Platelets
Description: sequencing miRNA from TEPs

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP - Tumor Educated Platelets
Description: sequencing miRNA from TEPs

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP - Tumor Educated Platelets
Description: sequencing miRNA from TEPs
Study: NCT05038943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragonix SherpaPak Cardiac Transport System
Description: Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
Study: NCT05702918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL-6000 FSWT
Description: The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Achilles Tendon Loading Exercise Protocol According to Silbernagel
Description: It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Achilles Tendon Loading Exercise Protocol According to Silbernagel
Description: It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
Study: NCT05069610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: A recombinant protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: A recombinant protein

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer)
Description: Formulation buffer

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer)
Description: Formulation buffer
Study: NCT05968131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy with Proprioceptive Training Exercises
Description: Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station.
Study: NCT05244993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
Study: NCT06306820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed PEEP
Description: Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lung recruitment
Description: Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized PEEP
Description: Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
Study: NCT05342935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inteligent Dialysis Assistant (IDA)
Description: The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
Study: NCT06314867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)
Description: All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)
Description: All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)
Description: All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
Study: NCT04862455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given intratumorally/intranodally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT04748146

Intervention type: OTHER
Group type: OTHER
Intervention: Brain stimulation
Description: Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
Study: NCT05702294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diary pod ( measuring vessel that automatically calculates voided volume)
Description: Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diary pod ( measuring vessel that automatically calculates voided volume)
Description: Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
Study: NCT06161064

Intervention type: DRUG
Group type: OTHER
Intervention: Hyaluronic acid
Description: hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency